While the EMA said the ‘probable link’ was found between the injection site and the ‘abnormal’ blood clot, the UK offers young people a risky method of vaccination.
On Wednesday, the AstraZeneca vaccine came under additional pressure as the European Union’s pharmaceutical regulator found a possible link between the vaccination and rare cases of blood clotting, when the UK vowed to give young people an alternative vaccine due to risk.
The European Medicines Agency’s (EMA) widely-awaited ruling on Wednesday after reviewing dozens of reports of an extremely rare blood clot in the brain, known as cerebral venous sinus thrombosis (CVST ).
It also concluded that abnormal blood clots with low platelet counts in the blood should be listed as a very rare side effect of the injection.
“The EMA is reminding health care professionals and vaccine recipients to be aware of the very rare possibility of a blood clot associated with a low blood platelet count,” the agency said. two weeks after vaccination ”.
“So far, most reported cases have occurred in women younger than 60 years old within two weeks of vaccination. Based on the available evidence, specific risk factors have not been confirmed ”.
In a separate development, the UK said people between the ages of 18 and 29 will be given an alternative vaccine to AstraZeneca due to the risk of blood clots.
This is the hot news story. More details to follow.